• Explore /
  • Poster
  • / PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+ osteosarcoma: A Children’s Oncology Group Pediatric Early-Phase Clinical Trial Network study.

PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+ osteosarcoma: A Children’s Oncology Group Pediatric Early-Phase Clinical Trial Network study.

Abstract Poster

Authors

Damon Reed

Damon R. Reed

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Damon R. Reed , Katherine A. Janeway , Charles G. Minard , David Hall , Brian D. Crompton , Alexander J. Lazar , Wei-Lien Wang , Stephan D. Voss , Olga Militano , Richard Greg Gorlick , Cheryl Ann Pickett-Gies , Elizabeth Fox , Brenda Weigel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Bone Tumors

Clinical Trial Registration Number

NCT04616560

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 11527)

DOI

10.1200/JCO.2023.41.16_suppl.11527

Abstract #

11527

Poster Bd #

461

Abstract Disclosures

Similar Posters

First Author: Akihiro Ohba

First Author: Kohei Shitara

First Author: Emanuela Palmerini

First Author: Fabrice Andre